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S40 Journal of Thoracic Oncology Vol. 11 No. 2Sand survival in lung cancer patients. The SNP, which
arose in Africa, modulates the splicing of MRPL43,
leading to a linear decrease in the major isoform and a
switch in the balance of oxidative phosphorylation and
glycolysis. Our work identiﬁes a new pathway of po-
tential relevance to lung cancer and provides new
insight into the role of mitochondrial ribosomes in
cancer.
Prognostic nomogram for predicting
survival of non-small-cell lung cancer
patients*
Jeong Seon Ryu, Bo-Rim Yi, Jung Soo Kim Inha
University Hospital, Incheon, Incheon, KoreaA few prognostic factors have been widely accepted in
non-small-cell lung cancer (NSCLC). Nomogram is a
useful tool of providing more accurate prognostic in-
formation in cancer patients. For the ﬁrst time, we tried
to develop prognostic nomogram for patients with stage
III/IV non-small-cell lung cancer (NSCLC) who seek
medical care in daily clinical practices.
Using the 15 pretreatment readily available clinical
variables in 752 patients with stage III/IV NSCLC, we
performed a Cox proportional hazard analysis with hi-
erarchical backward elimination methods to identify
survival prognostic factors. Then using these indepen-
dent prognostic factors, the prognostic nomogram was
constructed from data collected from a test group of 376
(50%) randomly sampled patients with NSCLC and it
was validated with data from the remaining 50% of the
patients.
The independent poor prognostic factors that were
included in the nomogram are as follows: male, weight
loss of more than 5%, Eastern Cooperative Oncology
Group performance status greater than 1, histology of no
squamous cell carcinoma, Tumor-Node-Metastasis stage
greater than IIIA, increased serum calcium, low serum
hemoglobin, and no chemotherapy. The prognostic
nomogram constructed from eight independent prog-
nostic factors predicted survival well with a concordance
index of 0.66, which was validated by an internal group
of patients.
We developed a unique prognostic nomogram con-
structed using pretreatment readily available clinical
variables to predict the probability of survival in NSCLC
patients. This prognostic nomogram may help re-
searchers in designing randomized clinical trials as well
as assist clinicians in selecting the most appropriate
therapy for NSCLC patients.* Due to unforeseen circumstance, this poster was not presented.High expression of endoplasmic
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Various conditions such as low oxygen and low
nutrition cause accumulation of unfolded or misfolded
proteins in the endoplasmic reticulum (ER), leading to
ER stress. To overcome this, cells have resistance
mechanisms called unfolded protein response (UPR).
When UPR is insufﬁcient, ER-mediated apoptosis oc-
curs. Recent reports have shown that several diseases
including cancers can be caused by ER stress. In
cancers, high proliferation rates and the presence of
mutated gene products lead to accumulation of
unfolded and misfolded proteins in the ER and adap-
tation to ER stress is essential for survival of cancer
cells.
As preliminary analysis, we used publicly available
expression proﬁles (GSE10245 and normal tissue
data sets) and analyzed expression levels of 84 ER
stress pathway genes. We found ER oxidoreductin 1L
(ERO1L) was highly expressed in many types of
cancer tissue, while expression was low in normal
tissues. In addition, using OncomineTM, we found
ERO1L high expression was associated with poor
prognosis of non-small cell lung cancer. There are
some reports that expression of ERO1L is beneﬁcial
to tumor cells, but association with lung cancer has
not been reported. Therefore , we sought to deter-
mine the role of ERO1L in lung cancer, including
response to therapy.
Using quantitative RT-PCR and Western blotting, we
identiﬁed NCI-H441, HCC2935, and NCI-H2347 as
ERO1L high expression cell lines. NCI-H520, NCI-
H522, and SK-LU-1 were ERO1L low expression cell
lines. We then exposed these cells to cisplatin (CDDP)
and determined the half maximal inhibitory concen-
tration (IC50). IC50 values for CDDP was 91, 64, and
21 mM, respectively, in cells with high ERO1L
expression. IC50 values for CDDP was 2.6, 4.1, and 22
mM, respectively, in cells with low ERO1L expression.
We then exposed cell lines to both CDDP and EN460,
an ERO1L inhibitor. When CDDP was combined with
low dose EN460 (1/10 of IC50), there was a trend
toward decreased IC50 for CDDP. We also evaluated
IC50 values for CDDP plus high dose EN460 (1/3 of
